Cost-effectiveness study comparing pharmaceutically licensed plasma for transfusion (OctaplasLG®) versus fresh frozen plasma (FFP) in critically Ill patients in the UK
| Autor: | Maria A. de Peuter, J.N. Mario Ouwens, Margreet C. van Eerd |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Discounted cost
medicine.medical_specialty Cost–benefit analysis Plasma Exchange Critically ill business.industry Cost effectiveness Cost-Benefit Analysis Critical Illness MEDLINE Hematology Cost-effectiveness analysis United Kingdom Quality-adjusted life year Plasma medicine Humans Fresh frozen plasma Quality-Adjusted Life Years Intensive care medicine business |
| Zdroj: | Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 43(3) |
| ISSN: | 1473-0502 |
| Popis: | This study evaluates the cost-effectiveness of OctaplasLG® (pharmaceutically licensed plasma for transfusion) versus fresh frozen plasma (FFP) in critically ill patients in the UK using a decision-analytic approach. Transfusion with OctaplasLG® resulted in 0.03 quality adjusted life years (QALYs) and 0.03 life years saved compared with FFP. The discounted cost per life year was £949 ($1504), and the discounted cost per QALY saved was £1030 ($1632) with OctaplasLG® in the UK. Based on a higher price of £70 ($111) for OctaplasLG® versus £28.42 ($45.04) for FFP, OctaplasLG® is considered to be cost-effective at a threshold of £30,000 ($47,548) per QALY. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect